|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003241,
umls-concept:C0006142,
umls-concept:C0013227,
umls-concept:C0034802,
umls-concept:C0069515,
umls-concept:C0086418,
umls-concept:C0087111,
umls-concept:C0242957,
umls-concept:C0282460,
umls-concept:C0301869,
umls-concept:C0332152,
umls-concept:C1446409,
umls-concept:C2826229
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-1-31
|
|
pubmed:abstractText |
The antibody-drug conjugate trastuzumab-DM1 (T-DM1) combines the biologic activity of trastuzumab with targeted delivery of a potent antimicrotubule agent, DM1, to human epidermal growth factor receptor 2 (HER2)-overexpressing cancer cells. Based on results from a phase I study that showed T-DM1 was well tolerated at the maximum-tolerated dose of 3.6 mg/kg every 3 weeks, with evidence of efficacy, in patients with HER2-positive metastatic breast cancer (MBC) who were previously treated with trastuzumab, we conducted a phase II study to further define the safety and efficacy of T-DM1 in this patient population.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/HER2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Immunotoxins,
http://linkedlifedata.com/resource/pubmed/chemical/Maytansine,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab-DM1 conjugate
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:AmlerLukasL,
pubmed-author:BorsonRachel ARA,
pubmed-author:BurrisHoward AHA3rd,
pubmed-author:ChuYu-WayeYW,
pubmed-author:GirishSandhyaS,
pubmed-author:KlenckeBarbaraB,
pubmed-author:KropIan EIE,
pubmed-author:LimentaniStevenS,
pubmed-author:MichaelsonRichard ARA,
pubmed-author:O'ShaughnessyJoyce AJA,
pubmed-author:RugoHope SHS,
pubmed-author:Tan-ChiuElizabethE,
pubmed-author:VogelCharles LCL,
pubmed-author:VukeljaSvetislava JSJ,
pubmed-author:ZhengMaoxiaM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
398-405
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21172893-Adult,
pubmed-meshheading:21172893-Aged,
pubmed-meshheading:21172893-Aged, 80 and over,
pubmed-meshheading:21172893-Antibodies, Monoclonal,
pubmed-meshheading:21172893-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21172893-Antineoplastic Agents,
pubmed-meshheading:21172893-Breast Neoplasms,
pubmed-meshheading:21172893-Disease-Free Survival,
pubmed-meshheading:21172893-Female,
pubmed-meshheading:21172893-Humans,
pubmed-meshheading:21172893-Immunotoxins,
pubmed-meshheading:21172893-Kaplan-Meier Estimate,
pubmed-meshheading:21172893-Maytansine,
pubmed-meshheading:21172893-Middle Aged,
pubmed-meshheading:21172893-RNA, Messenger,
pubmed-meshheading:21172893-Receptor, erbB-2,
pubmed-meshheading:21172893-Time Factors,
pubmed-meshheading:21172893-Treatment Outcome,
pubmed-meshheading:21172893-United States
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
|
|
pubmed:affiliation |
Sarah Cannon Research Institute, Nashville, TN 37203-1632, USA. howard.burris@scresearch.net
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II
|
